ClinicalTrials.gg
CompletedNCT02065882Updated Jul 3, 2025Results posted

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

A Phase 3 interventional study of BT524 (Part I) and BT524 (Part II) in Congenital Afibrinogenemia and Congenital Hypofibrinogenemia, sponsored by Biotest. Completed at 6 sites in 5 countries. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Biotest (part of Grifols) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2013, registered Feb 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
Up to 75 Years
Sex
All
01

Study summary

This was a prospective, open-label, multicenter, phase I/III study investigating the 14-day single-dose pharmacokinetic and pharmacodynamic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.

Read the detailed description

The study was divided into two parts (Part I and Part II). Part I focused on the primary endpoint of the study, 14-day single-dose pharmacokinetics (PK) and 14-day single-dose pharmacodynamics (PD), as well as the assessment of maximum clot firmness (MCF) as a surrogate parameter for efficacy. Part I of the study was followed by Part II, which evaluated the efficacy and safety of single and repetitive administration of BT524 in patients undergoing on-demand prophylaxis (ODP) and/or on-demand treatment (ODT) for various bleeding events [e.g., elective surgery, spontaneous or post-traumatic major bleeding]. All patients who participated in the PK assessment (Part I) without severe post-administration complications ideally continued treatment with BT524 for ODP and/or ODT in Part II.

02

Conditions studied

  • Congenital Afibrinogenemia
  • Congenital Hypofibrinogenemia

Keywords

  • fibrinogen, bleeding,
03

In context

Afibrinogenemia

32 studies on the registry are indexed under Afibrinogenemia; 5 are open to participants now.

This study's enrollment of 67 is above the median of 40 across 19 interventional studies indexed under Afibrinogenemia.

Browse Afibrinogenemia studies →

Lead sponsor

Biotest is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

First submitted before Biotest became part of Grifols.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known congenital afibrinogenemia or severe congenital hypofibrinogenemia
  • Plasma fibrinogen activity ≤ 0.5 g/l and antigen ≤ 0.5 g/l
  • Male or female
  • Age 0 to 75 years, with the first ten patients will be 18 years or older
  • Presumed to be compliant with the study procedures and to terminate the study as scheduled
  • Willing and able to be hospitalized for 3 days for the pharmacokinetic assessment (if applicable)
  • Willing and able to be hospitalized - if required - in case of interventions (e.g., surgical procedures, major bleeds)
  • Written by the patient, his/her parents or by the patient's legal/authorized representative as applicable

Exclusion criteria

Exclusion Criteria:

  • Known congenital dysfibrinogenemia (not applicable for adult patients with hypodysfibrinogenemia in study part II)
  • Known bleeding disorder other than congenital fibrinogen deficiency
  • History of esophageal variceal bleeding
  • Known presence or history of venous/arterial thrombosis or thromboembolic event in the preceding 6 months
  • Known presence or history of fibrinogen inhibitory antibodies
  • Known presence or history of to human fibrinogen or human plasma proteins e.g., immunoglobulins, vaccines or hypersensitivity to any of the
  • Known positive serology for -1 and HIV-2
  • biochemical or hematological findings (except due to underlying disease or emergency bleeding) outside the normal range (at the investigator's discretion)
  • Clinically relevant pathological findings in physical examination including
  • Treatment with any fibrinogen concentrate and/or fibrinogen-containing product within 2 weeks prior to infusion of BT524
  • Concomitant medication interacting relevantly with the coagulation system such as: low molecular weight heparin or unfractioned heparin, factor Xa inhibitors, thrombin inhibitors (factor II a inhibitors), antiplatelet drugs (PY12 inhibitors) within 2 weeks prior to infusion of BT524
  • Recent vaccination (within 3 weeks prior to infusion)
  • Body weight (BW) below 22 kg for patients ≥ 6 years; BW below the 5th percentile of the normal range for children \< 6 years (refers to local standards)
  • End stage disease
  • Abuse of drugs
  • Unable to understand and follow the study requirements
  • Participation in another interventional clinical study within 30 days before entering the study or during the study
  • Pregnant/ nursing woman, or woman of not using reliable/ effective method(s) during the study and at least one month after the last administration of study drug (e.g., oral/ injectable/ implantable/ insertable/ topical hormonal contraceptives, intrauterine devices, female sterilization, partner's vasectomy or condoms)
  • Any other condition that, to the investigator's judgment, could have an impact on patient's safety or the study results
  • Elective surgery during the 14 day PK blood sampling period
  • Acute infection
  • Clinically relevant increase or decrease in body temperature
  • Actively bleeding or anticipated bleeding (including female menorrhea) at the time point of or within 7 days prior to infusion of BT524
  • Surgery within 7 days prior to infusion of BT524
  • Immobilization within 7 days prior to infusion of BT524
  • Intake of alcohol or significantly increased intake of caffeine containing products within 24 hours prior to infusion of BT524
  • Blood donation or comparable blood loss within 60 days prior to infusion of BT524
  • Excessive physical exercise (extreme sports activities, sauna) within 72 hours prior to infusion of BT524
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    BT524

    Part I: A single intravenous infusion of BT524 for assessment of PK/PD of BT524. Part II: A single or repetitive intravenous infusion(s) of BT524 for on-demand prophylaxis/on-demand treatment of bleeding events.

    Drug: BT524 (Part I) · Drug: BT524 (Part II)

Interventions

  • DrugBT524 (Part I)

    Single intravenous infusion of 70 mg BT524 per kg body weight.

    Also known as: Human Fibrinogen Concentrate

  • DrugBT524 (Part II)

    Single or repetitive intravenous infusion(s) of BT524, depending on the severity of the disorder, location and extent of the bleeding and patient's clinical condition. Dosage based on individual body weight and fibrinogen level.

    Also known as: Human Fibrinogen Concentrate

06

What researchers measure

Primary outcomes

  1. Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen

    T1/2 of fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. T1/2 was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  2. Single-dose Pharmacokinetics (PK) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Antigen

    Time of occurence of Cmax relative to dosing (Tmax) for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Tmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  3. Single-Dose Pharmacokinetics (PK) for BT524: Maximum Concentration (Cmax) for Fibrinogen Antigen

    Maximum observed plasma concentration (Cmax) for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Cmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  4. Single-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Antigen

    AUC0-tz: Area under the time course of the plasma concentrations calculated from time zero up to the last quantifiable plasma concentration for fibrinogen antigen, was determined from samples taken at several time points during the 14 day sampling period. AUC0-tz was derived from time-concentration profiles using adapted methodology (noncompartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  5. Single-Dose Pharmacokinetics (PK) for BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Antigen

    AUCextr: extent of AUC extrapolation beyond last concentration for fibrinogen antigen, was determined from samples taken at several time points during the 14 day sampling period. AUCextr was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  6. Single-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Antigen

    AUC0-∞: AUC from time 0 to infinity for fibrinogen antigen, was determined from samples taken at several time points during the 14 day sampling period. AUC0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  7. Single-Dose Pharmacokinetics (PK) for BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Antigen

    MRT0-∞: Mean Residence Time (MRT) extrapolated to infinity for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. MRT0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  8. Single-Dose Pharmacokinetics (PK) for BT524: Clearance (CL) for Fibrinogen Antigen

    CL: Total clearance (CL) for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. CL was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  9. Single-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Antigen

    Vdss: Volume of distribution at presumed steady-state for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Vdss was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  10. Single-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Antigen

    Vdss per kg BW: Volume of distribution at presumed steady-state per kg bodyweight for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Vdss per kg BW was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  11. Single-Dose Pharmacokinetics (PK) for BT524: Incremental Recovery (IR) for Fibrinogen Antigen

    IR is the dose-adjusted maximum fibrinogen increase in plasma within 4 hours after the end of infusion.

    Time frame: Between pre-dose and 4 hours post-dose

  12. Single-Dose Pharmacokinetics (PK) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Antigen

    CIR: maximum fibrinogen increase in plasma within 4 hours after the end of infusion divided by the maximum theoretical fibrinogen increase

    Time frame: Between pre-dose and 4 hours post-dose

Secondary outcomes

  1. Single-dose Pharmacodynamics (PD) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Activity

    T1/2 of fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. T1/2 was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  2. Single-dose Pharmacodynamics (PD) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Activity

    Time of occurence of Cmax relative to dosing (Tmax) for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Tmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  3. Single-dose Pharmacodynamics (PD) of BT524: Maximum Concentration (Cmax) for Fibrinogen Activity

    Maximum observed plasma concentration (Cmax) for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Cmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  4. Single-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Activity

    AUC0-tz: Area under the time course of the plasma concentrations calculated from time zero up to the last quantifiable plasma concentration for fibrinogen activity, was determined from samples taken at several time points during the 14 day sampling period. AUC0-tz was derived from time-concentration profiles using adapted methodology (noncompartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  5. Single-dose Pharmacodynamics (PD) of BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Activity

    AUCextr: extent of AUC extrapolation beyond last concentration for fibrinogen activity, was determined from samples taken at several time points during the 14 day sampling period. AUCextr was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  6. Single-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Activity

    AUC0-∞: AUC from time 0 to infinity for fibrinogen activity, was determined from samples taken at several time points during the 14 day sampling period. AUC0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  7. Single-dose Pharmacodynamics (PD) of BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Activity

    MRT0-∞: Mean Residence Time (MRT) extrapolated to infinity for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. MRT0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  8. Single-Dose Pharmacodynamics (PD) for BT524: Clearance (CL) for Fibrinogen Activity

    CL: Total clearance (CL) for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. CL was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  9. Single-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Activity

    Vdss: Volume of distribution at presumed steady-state for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Vdss was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  10. Single-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Activity

    Vdss per kg BW: Volume of distribution at presumed steady-state per kg bodyweight for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Vdss per kg BW was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

    Time frame: Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose

  11. Single-Dose Pharmacodynamics (PD) for BT524: Incremental Recovery (IR) for Fibrinogen Activity

    IR is the dose-adjusted maximum fibrinogen increase in plasma within 4 hours after the end of infusion.

    Time frame: Between pre-dose and 4 hours post-dose

  12. Single-Dose Pharmacodynamics (PD) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Activity

    CIR: maximum fibrinogen increase in plasma within 4 hours after the end of infusion divided by the maximum theoretical fibrinogen increase

    Time frame: Between pre-dose and 4 hours post-dose

  13. Change in Maximum Clot Firmness at 1 Hour Post-end of Infusion

    Maximum Clot Firmness (MCF), assessed by rotational thromboelastometry (ROTEM), was used as a surrogate marker of haemostatic efficacy following administration of BT524. In Part I, MCF was measured before and 1 hour after the end of a single BT524 infusion. In Part II, MCF was measured before and 1 hour after the end of each BT524 infusion administered to treat bleeding events. The variable was the change in MCF from pre-dose to 1 hour post-end of infusion.

    Time frame: Part I: pre-dose and at 1 hour post-end of infusion. Part II: pre-dose and at 1 hour post-end of infusion of each bleeding event.

  14. Clinical Efficacy for BT524: Overall Hemostatic Response to Treatment With BT524 in Study Part II

    Overall hemostatic response (OHR) to treatment with BT524 for each surgical procedure and each treated bleed was rated on a 4-point scale ("none", "moderate", "good" or "excellent"). The sum of good and excellent ratings was defined as "success" in the analysis. Frequencies and percentages of OHR on event level (Success rate in % = number of successfully treated bleeding events / total number of bleeding events).

    Time frame: Part II: Up to 24 hours after end of infusion, or on day of hospital discharge (if between 24 hours and 49 days post-infusion); at the latest on day 49 after the treated bleeding event.

  15. Clinical Efficacy for BT524: Total Loss of Blood for Surgical Bleeding Events in Study Part II

    Total loss of blood was rated by the investigator per surgical bleeding events (eg, intra- and post-operatively, rebleedings) using the classifications of "lower than expected", "within the expected range", and "higher than expected". The ratings were analyzed descriptively (frequencies and percentages) on event level for the Full Bleeding Event Set (FBE).

    Time frame: Part II: Up to 24 hours after end of infusion, or on day of hospital discharge (if between 24 hours and 49 days post-infusion); at the latest on day 49 after the treated bleeding event.

  16. Clinical Efficacy for BT524: Units of Other Fibrinogen-containing Products (FCP) Infused Besides BT524 in Study Part II

    Units of other fibrinogen-containing products (FCP) infused besides BT524 eg, fresh frozen plasma (FFP) or cryoprecipitate or alternative commercially available fibrinogen concentrates given to counteract hemodynamic instability were documented and analyzed descriptively on event level for the FBE.

    Time frame: Part II: Up to 24 hours after end of infusion, or on day of hospital discharge (if between 24 hours and 49 days post-infusion); at the latest on day 49 after the treated bleeding event.

07

Results

Posted Jul 3, 2025

Participant flow

Part I and Part II of the study were conducted consecutively, enrolling a total of 67 participants. The total number of participants enrolled (N=67) is smaller than the sum of participants enrolled in Part I (N=35) and Part II (N=59), because 27 participants who successfully completed Part I were subsequently enrolled in Part II. Of the enrolled participants, N=27 in Part I and N=36 in Part II were treated with BT524, with 18 participants receiving BT524 in both parts of the study.

Part I: PK/PD
Participant flow — Part I: PK/PD
MilestoneBT542 (Human Fibrinogen Concentrate)
Started35
Treated27
Completed27
Not completed8
Withdrew: Screening failure5
Withdrew: Withdrawal by subject2
Withdrew: Adverse event1
Part II: Clinical Efficacy
Participant flow — Part II: Clinical Efficacy
MilestoneBT542 (Human Fibrinogen Concentrate)
Started59
Treated36
Completed28
Not completed31
Withdrew: Screening failure7
Withdrew: Withdrawal by subject2
Withdrew: Adverse event5
Withdrew: Regulatory authority decision3
Withdrew: No bleeding event11
Withdrew: Protocol violation3

Outcome measures

PrimarySingle-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen

T1/2 of fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. T1/2 was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · hours
Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen
hoursBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen67.9 ± 15.3
PrimarySingle-dose Pharmacokinetics (PK) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Antigen

Time of occurence of Cmax relative to dosing (Tmax) for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Tmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · hours
Single-dose Pharmacokinetics (PK) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Antigen
hoursBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacokinetics (PK) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Antigen0.843 ± 0.361
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Maximum Concentration (Cmax) for Fibrinogen Antigen

Maximum observed plasma concentration (Cmax) for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Cmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · g/L
Single-Dose Pharmacokinetics (PK) for BT524: Maximum Concentration (Cmax) for Fibrinogen Antigen
g/LBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Maximum Concentration (Cmax) for Fibrinogen Antigen1.81 ± 0.423
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Antigen

AUC0-tz: Area under the time course of the plasma concentrations calculated from time zero up to the last quantifiable plasma concentration for fibrinogen antigen, was determined from samples taken at several time points during the 14 day sampling period. AUC0-tz was derived from time-concentration profiles using adapted methodology (noncompartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · g*h/L
Single-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Antigen
g*h/LBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Antigen144 ± 38.9
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Antigen

AUCextr: extent of AUC extrapolation beyond last concentration for fibrinogen antigen, was determined from samples taken at several time points during the 14 day sampling period. AUCextr was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · percentage
Single-Dose Pharmacokinetics (PK) for BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Antigen
percentageBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Antigen17.1 ± 3.58
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Antigen

AUC0-∞: AUC from time 0 to infinity for fibrinogen antigen, was determined from samples taken at several time points during the 14 day sampling period. AUC0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · g*h/L
Single-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Antigen
g*h/LBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Antigen173 ± 45.4
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Antigen

MRT0-∞: Mean Residence Time (MRT) extrapolated to infinity for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. MRT0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · hours
Single-Dose Pharmacokinetics (PK) for BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Antigen
hoursBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Antigen133 ± 17.4
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Clearance (CL) for Fibrinogen Antigen

CL: Total clearance (CL) for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. CL was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · L/h
Single-Dose Pharmacokinetics (PK) for BT524: Clearance (CL) for Fibrinogen Antigen
L/hBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Clearance (CL) for Fibrinogen Antigen0.0206 ± 0.00961
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Antigen

Vdss: Volume of distribution at presumed steady-state for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Vdss was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · Liter
Single-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Antigen
LiterBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Antigen2.70 ± 1.34
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Antigen

Vdss per kg BW: Volume of distribution at presumed steady-state per kg bodyweight for fibrinogen antigen was determined from samples taken at several time points during the 14 day sampling period. Vdss per kg BW was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · mL/kg
Single-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Antigen
mL/kgBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Antigen57.8 ± 19.1
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Incremental Recovery (IR) for Fibrinogen Antigen

IR is the dose-adjusted maximum fibrinogen increase in plasma within 4 hours after the end of infusion.

Time frame:
Between pre-dose and 4 hours post-dose
Reported as:
Mean · (mg/dL)/(mg/kg dose)
Single-Dose Pharmacokinetics (PK) for BT524: Incremental Recovery (IR) for Fibrinogen Antigen
(mg/dL)/(mg/kg dose)BT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Incremental Recovery (IR) for Fibrinogen Antigen2.63 ± 0.652
PrimarySingle-Dose Pharmacokinetics (PK) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Antigen

CIR: maximum fibrinogen increase in plasma within 4 hours after the end of infusion divided by the maximum theoretical fibrinogen increase

Time frame:
Between pre-dose and 4 hours post-dose
Reported as:
Mean · % of expected increase in fibrinogen
Single-Dose Pharmacokinetics (PK) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Antigen
% of expected increase in fibrinogenBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacokinetics (PK) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Antigen118 ± 29.4
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Activity

T1/2 of fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. T1/2 was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · hours
Single-dose Pharmacodynamics (PD) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Activity
hoursBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Activity60.3 ± 13.3
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Activity

Time of occurence of Cmax relative to dosing (Tmax) for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Tmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · hours
Single-dose Pharmacodynamics (PD) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Activity
hoursBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Time to Maximum Concentration (Tmax) for Fibrinogen Activity0.843 ± 0.361
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Maximum Concentration (Cmax) for Fibrinogen Activity

Maximum observed plasma concentration (Cmax) for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Cmax was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · g/L
Single-dose Pharmacodynamics (PD) of BT524: Maximum Concentration (Cmax) for Fibrinogen Activity
g/LBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Maximum Concentration (Cmax) for Fibrinogen Activity1.26 ± 0,396
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Activity

AUC0-tz: Area under the time course of the plasma concentrations calculated from time zero up to the last quantifiable plasma concentration for fibrinogen activity, was determined from samples taken at several time points during the 14 day sampling period. AUC0-tz was derived from time-concentration profiles using adapted methodology (noncompartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · g*h/L
Single-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Activity
g*h/LBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) Calculated to the Last Measured Concentration (AUC0-tz) for Fibrinogen Activity88.2 ± 29.3
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Activity

AUCextr: extent of AUC extrapolation beyond last concentration for fibrinogen activity, was determined from samples taken at several time points during the 14 day sampling period. AUCextr was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · percentage (extent of AUC extrapolation)
Single-dose Pharmacodynamics (PD) of BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Activity
percentage (extent of AUC extrapolation)BT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Extent of Area Under the Curve (AUC) Extrapolation Beyond Last Concentration (AUCextr) for Fibrinogen Activity15.4 ± 3.41
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Activity

AUC0-∞: AUC from time 0 to infinity for fibrinogen activity, was determined from samples taken at several time points during the 14 day sampling period. AUC0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · g*h/L
Single-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Activity
g*h/LBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Area Under the Curve (AUC) From Time 0 to Infinity (AUC0-∞) for Fibrinogen Activity104 ± 33.5
SecondarySingle-dose Pharmacodynamics (PD) of BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Activity

MRT0-∞: Mean Residence Time (MRT) extrapolated to infinity for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. MRT0-∞ was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · hours
Single-dose Pharmacodynamics (PD) of BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Activity
hoursBT524 (Human Fibrinogen Concentrate)
Single-dose Pharmacodynamics (PD) of BT524: Mean Residence Time (MRT) Extrapolated to Infinity (MRT0-∞) for Fibrinogen Activity124 ± 16.2
SecondarySingle-Dose Pharmacodynamics (PD) for BT524: Clearance (CL) for Fibrinogen Activity

CL: Total clearance (CL) for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. CL was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · L/h
Single-Dose Pharmacodynamics (PD) for BT524: Clearance (CL) for Fibrinogen Activity
L/hBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacodynamics (PD) for BT524: Clearance (CL) for Fibrinogen Activity0.0351 ± 0.0179
SecondarySingle-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Activity

Vdss: Volume of distribution at presumed steady-state for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Vdss was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · Liter
Single-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Activity
LiterBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) for Fibrinogen Activity4.31 ± 2.36
SecondarySingle-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Activity

Vdss per kg BW: Volume of distribution at presumed steady-state per kg bodyweight for fibrinogen activity was determined from samples taken at several time points during the 14 day sampling period. Vdss per kg BW was derived from time-concentration profiles using adapted methodology (non-compartmental analysis, compartment analysis, or population modeling, as appropriate/ required).

Time frame:
Pre-dose on Dosing Day 0, at the end of the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 240 and 336 hours post-dose
Reported as:
Mean · mL/kg
Single-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Activity
mL/kgBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacodynamics (PD) for BT524: Volume of Distribution at Presumed Steady-state (Vdss) Per kg Body Weight (BW) for Fibrinogen Activity92.4 ± 34.7
SecondarySingle-Dose Pharmacodynamics (PD) for BT524: Incremental Recovery (IR) for Fibrinogen Activity

IR is the dose-adjusted maximum fibrinogen increase in plasma within 4 hours after the end of infusion.

Time frame:
Between pre-dose and 4 hours post-dose
Reported as:
Mean · (mg/dL)/(mg/kg dose)
Single-Dose Pharmacodynamics (PD) for BT524: Incremental Recovery (IR) for Fibrinogen Activity
(mg/dL)/(mg/kg dose)BT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacodynamics (PD) for BT524: Incremental Recovery (IR) for Fibrinogen Activity1.88 ± 0.610
SecondarySingle-Dose Pharmacodynamics (PD) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Activity

CIR: maximum fibrinogen increase in plasma within 4 hours after the end of infusion divided by the maximum theoretical fibrinogen increase

Time frame:
Between pre-dose and 4 hours post-dose
Reported as:
Mean · % of expected increase in fibrinogen
Single-Dose Pharmacodynamics (PD) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Activity
% of expected increase in fibrinogenBT524 (Human Fibrinogen Concentrate)
Single-Dose Pharmacodynamics (PD) for BT524: Classical in Vivo Recovery (CIR) for Fibrinogen Activity84.8 ± 27.5
SecondaryChange in Maximum Clot Firmness at 1 Hour Post-end of Infusion

Maximum Clot Firmness (MCF), assessed by rotational thromboelastometry (ROTEM), was used as a surrogate marker of haemostatic efficacy following administration of BT524. In Part I, MCF was measured before and 1 hour after the end of a single BT524 infusion. In Part II, MCF was measured before and 1 hour after the end of each BT524 infusion administered to treat bleeding events. The variable was the change in MCF from pre-dose to 1 hour post-end of infusion.

Time frame:
Part I: pre-dose and at 1 hour post-end of infusion. Part II: pre-dose and at 1 hour post-end of infusion of each bleeding event.
Reported as:
Mean · mm
Change in Maximum Clot Firmness at 1 Hour Post-end of Infusion
mmPart IPart II
Adults11.1 ± 5.0711.1 ± 5.55
Adolescents, 12 to <18 years11.0 ± 2.839.8 ± 5.28
Children, 6 to <12 years16.5 ± 3.5411.1 ± 4.57
Children, <6 years9.3 ± 1.538.7 ± 5.51
Statistical analysis
  • Part I · t-test, 2 sided · p = <0.0001
SecondaryClinical Efficacy for BT524: Overall Hemostatic Response to Treatment With BT524 in Study Part II

Overall hemostatic response (OHR) to treatment with BT524 for each surgical procedure and each treated bleed was rated on a 4-point scale ("none", "moderate", "good" or "excellent"). The sum of good and excellent ratings was defined as "success" in the analysis. Frequencies and percentages of OHR on event level (Success rate in % = number of successfully treated bleeding events / total number of bleeding events).

Time frame:
Part II: Up to 24 hours after end of infusion, or on day of hospital discharge (if between 24 hours and 49 days post-infusion); at the latest on day 49 after the treated bleeding event.
Reported as:
Count of units · Bleeding Events
Clinical Efficacy for BT524: Overall Hemostatic Response to Treatment With BT524 in Study Part II
Bleeding EventsPart II
Excellent150
Good23
Moderate2
None0
SecondaryClinical Efficacy for BT524: Total Loss of Blood for Surgical Bleeding Events in Study Part II

Total loss of blood was rated by the investigator per surgical bleeding events (eg, intra- and post-operatively, rebleedings) using the classifications of "lower than expected", "within the expected range", and "higher than expected". The ratings were analyzed descriptively (frequencies and percentages) on event level for the Full Bleeding Event Set (FBE).

Time frame:
Part II: Up to 24 hours after end of infusion, or on day of hospital discharge (if between 24 hours and 49 days post-infusion); at the latest on day 49 after the treated bleeding event.
Reported as:
Count of units · Surgical bleeding events
Clinical Efficacy for BT524: Total Loss of Blood for Surgical Bleeding Events in Study Part II
Surgical bleeding eventsPart II
Loss of blood is lower than expected for the procedure performed.3
Loss of blood is within the expected range for the procedure performed.45
Loss of blood is higher than expected for the procedure performed.4
Missing2
SecondaryClinical Efficacy for BT524: Units of Other Fibrinogen-containing Products (FCP) Infused Besides BT524 in Study Part II

Units of other fibrinogen-containing products (FCP) infused besides BT524 eg, fresh frozen plasma (FFP) or cryoprecipitate or alternative commercially available fibrinogen concentrates given to counteract hemodynamic instability were documented and analyzed descriptively on event level for the FBE.

Time frame:
Part II: Up to 24 hours after end of infusion, or on day of hospital discharge (if between 24 hours and 49 days post-infusion); at the latest on day 49 after the treated bleeding event.
Reported as:
Number · Number of FCP
Clinical Efficacy for BT524: Units of Other Fibrinogen-containing Products (FCP) Infused Besides BT524 in Study Part II
Number of FCPPart II
Clinical Efficacy for BT524: Units of Other Fibrinogen-containing Products (FCP) Infused Besides BT524 in Study Part II0

Adverse events

Collected over Day 0 to Day 49 (From the day of study drug administration until 49±4 days after the last administration of the study drug in Part I, up to 1 year in Part II.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PK/PD Part I0/27 (0%)2/27 (7.4%)10/27 (37%)
Part II1/36 (2.8%)7/36 (19.4%)25/36 (69.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPK/PD Part IPart II
Pain in extremityMusculoskeletal and connective tissue disorders1/270/36
Hypertensive encephalopathyNervous system disorders1/270/36
Post streptococcal glomerulonephritisRenal and urinary disorders1/270/36
Iron deficiency anaemiaBlood and lymphatic system disorders0/271/36
PancreatitisGastrointestinal disorders0/271/36
Portal vein thrombosisHepatobiliary disorders0/271/36
Extradural heamatomaInjury, poisoning and procedural complications0/271/36
Traumatic haemorrhageInjury, poisoning and procedural complications0/271/36
Haematoma muscleMusculoskeletal and connective tissue disorders0/271/36
EpilepsyNervous system disorders0/271/36
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPK/PD Part IPart II
Procedural painInjury, poisoning and procedural complications0/279/36
Subcutaneous haematomaInjury, poisoning and procedural complications1/276/36
Back painMusculoskeletal and connective tissue disorders3/274/36
Pain in extremityMusculoskeletal and connective tissue disorders0/274/36
EpistaxisRespiratory, thoracic and mediastinal disorders0/274/36
ToothacheGastrointestinal disorders2/273/36
PyrexiaGeneral disorders1/273/36
Swelling faceGeneral disorders0/273/36
Traumatic haematomaInjury, poisoning and procedural complications0/273/36
OsteorrhagiaMusculoskeletal and connective tissue disorders0/273/36

Baseline characteristics

Part I: Baseline characteristics were assessed in all participants who received any portion of BT524 (n=27). Part II: Baseline characteristics were assessed in all participants who received any portion of BT524 (n=36).

Age, Categorical
Age, Categorical(Participants)BT524 (Human Fibrinogen Concentrate)
Part I — <=18 years12
Part I — Between 18 and 65 years15
Part I — >=65 years0
Part II — <=18 years16
Part II — Between 18 and 65 years20
Part II — >=65 years0
Age, Continuous
Age, Continuous(years)BT524 (Human Fibrinogen Concentrate)
Part I17.6 ± 11.82
Part II19.6 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)BT524 (Human Fibrinogen Concentrate)
Part I — Female13
Part I — Male14
Part II — Female14
Part II — Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BT524 (Human Fibrinogen Concentrate)
Part I — Hispanic or Latino0
Part I — Not Hispanic or Latino27
Part I — Unknown or Not Reported0
Part II — Hispanic or Latino0
Part II — Not Hispanic or Latino36
Part II — Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BT524 (Human Fibrinogen Concentrate)
Part I — American Indian or Alaska Native0
Part I — Asian0
Part I — Native Hawaiian or Other Pacific Islander0
Part I — Black or African American1
Part I — White26
Part I — More than one race0
Part I — Unknown or Not Reported0
Part II — American Indian or Alaska Native0
Part II — Asian0
Part II — Native Hawaiian or Other Pacific Islander0
Part II — Black or African American0
Part II — White36
Part II — More than one race0
Part II — Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)BT524 (Human Fibrinogen Concentrate)
Lebanon39
Egypt12
Bulgaria2
Tunisia13
Germany1
Maximum Clot Firmness
Maximum Clot Firmness(mm)BT524 (Human Fibrinogen Concentrate)
Part I: Adults1.2 ± 0.58
Part I: Adolescents, 12 to <18 years1.0 ± 0
Part I: Children, 6 to <12 years1.0 ± 0
Part I: Children, <6 years1.0 ± 0
Part II: Adults2.1 ± 4.03
Part II: Adolescents, 12 to <18 years1.0 ± 0
Part II: Children, 6 to <12 years1.0 ± 0
Part II: Children, <6 years1.0 ± 0
Fibrinogen Activity
Fibrinogen Activity(g/L)BT524 (Human Fibrinogen Concentrate)
Part I: Adults0.1750 ± 0
Part I: Adolescents, 12 to <18 years0.1750 ± 0
Part I: Children, 6 to <12 years0.1750 ± 0
Part I: Children, <6 years0.1500 ± 0
Part II: Adults0.1681 ± 0.01856
Part II: Adolescents, 12 to <18 years0.1578 ± 0.01611
Part II: Children, 6 to <12 years0.1553 ± 0.02385
Part II: Children, <6 years0.1500 ± 0

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Site 15
    Sofia, Bulgaria
  • Site 11
    Cairo, Egypt
  • Site 16
    Frankfurt, Germany
  • Site 01
    Beirut, Lebanon
  • Site 14
    Sousse, Tunisia
  • Site12
    Tunis, Tunisia
09

References and documents

Publications

  • Khayat CD, El-Beshlawy A, Omar N, Belhadjali EG, Khelif A, Adolf S, Miesbach W, Aigner S, Abraha S, Schuettrumpf J, Boehm H. Efficacy and safety of prophylaxis and treatment of bleeding events with a novel fibrinogen concentrate from human plasma in patients with congenital fibrinogen deficiency. Thromb Res. 2026 Mar;259:109616. doi: 10.1016/j.thromres.2026.109616. Epub 2026 Feb 10. PubMed 41702298 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in May 2020, 86 months.

Results were first posted in Jul 2025, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2014
First posted
Feb 19, 2014
StartActual
Mar 2013
Primary completionActual
May 18, 2020
CompletionActual
Nov 18, 2020
Results first posted
Jul 3, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065882
Lead sponsor
Biotest
Collaborators
ICON plc, Phoenix Clinical Research, Accovion GmbH
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Mar 2013
Primary completion
May 18, 2020
Completion
Nov 18, 2020
Results posted
Jul 3, 2025
Last update
Jul 3, 2025

Study contacts

Claudia Djambas Khayat, MD
principal investigator · Hôtel Dieu de France, Dept. of Pediatrics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion